Bristol Myers Squibb Wins FDA Approval for Its First CELMoD Drug, Aimed at Multiple ...

Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS (iberdomide), its first CELMoD therapy, targeting multiple myeloma patients after just one relapse, offering a new treatment option and potential revenue growth for the company amid generic competition.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.